Accessibility Menu
Proteonomix logo

Proteonomix(OTC) PROT

Market Cap$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-58%
1 Year+9,900%
1 Month+25%
$0.00
+0.00%
+0.00Today
Proteonomix last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-20
Proteonomix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+25%USD 0.002026-05-14
1 month+25%USD 0.002026-05-14
3 month+25%USD 0.002026-05-14
Year to date+9,900%USD 0.002025-12-29
1 year+9,900%USD 0.002025-08-13
3 year+9,900%USD 0.002023-07-21
5 year-58.33%USD 0.002021-08-05
Since inception-100%USD 3.502006-10-03

Proteonomix Financials at a Glance

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.32K

Net Income (TTM)

-$1.56M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

14.95 (High)

Price

$0.00

Volume

31,075

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 1, 2024

PROT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Proteonomix

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics utilizing human cells and their derivatives. The company offers innovative products aimed at addressing various health conditions, including skin aging and liver disease.

Products and Services
  • Proteoderm: An anti-aging skin cream that reduces wrinkles
  • UMK-121: A treatment for liver disease using approved drugs to mobilize stem cells
  • StromaCel: A cardiac treatment using stem cells to repair heart tissue
Growth Outlook
  • Recent advancements in stem cell therapies show increasing market demand
  • Expansion into new therapeutic areas could enhance product offerings
  • Strategic partnerships may accelerate research and development efforts
Financial Highlights
  • Recent quarterly revenue of $2,290 indicates potential for growth
  • Net income for Q2 2012 was $1,444,000, showcasing operational efficiency
  • Cash and cash equivalents stood at $2,398,357, providing liquidity for operations
Proteonomix, Inc. operates in the dynamic biotechnology sector, focusing on innovative solutions for health challenges. The company's product lineup, including Proteoderm, UMK-121, and StromaCel, addresses significant market needs, particularly in anti-aging and regenerative medicine. The growth outlook is promising, with potential expansion into new therapeutic areas and strategic partnerships that could enhance research and development capabilities. Financially, the company has shown a recent quarterly revenue of $2,290, alongside a notable net income of $1,444,000 in Q2 2012, reflecting operational efficiency. With cash and cash equivalents of $2,398,357, Proteonomix is positioned to support its ongoing operations and future growth initiatives.
AI Generated • Jul 31, 2026

Industry

Biotechnology

Headquarters

Hawthorne, NJ 07506, US

PROT Financials

Key Financial Metrics (TTM)

Gross Margin

101.97%

Operating Margin

-5026.15%

Net Income Margin

-5322.26%

Return on Equity

38.77%

Return on Capital

N/A

Return on Assets

-41.42%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.81M

Volume

31.07K

Avg. Volume

0

Financials (TTM)

Gross Profit

$23.40K

Operating Income

-$3.75M

EBITDA

-$1.12M

Operating Cash Flow

-$1.27M

Capital Expenditure

-$77.97K

Free Cash Flow

-$1.35M

Cash & ST Invst.

$2.40M

Total Debt

$3.22M

Proteonomix Performance Analysis

Proteonomix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32011-09-30N/A
Q42011-12-31-0.1%
Q12012-03-31-67.3%
Q22012-06-30-100.0%
Proteonomix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32011-09-30-37.6%
Q42011-12-314.8%
Q12012-03-31-390.4%
Q22012-06-30164.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2012YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.98

N/A

Employees

164

N/A

Net Income

$1.44M

+627.0%

EBITDA

$1.54M

+1170.8%

Quarterly Fundamentals

Name
Q2 2012YOY CHG

Total Cash

$2.40M

+466506.4%

Total Debt

$3.22M

-13.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$3.22M

-13.5%

Return on Assets

-41.42%

N/A

Return on Invested Capital

35.35%

N/A

Free Cash Flow

-$595.08K

-1204.3%

Operating Cash Flow

-$560.59K

-1128.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMMHOmnimmune Holdings, Inc.
$0.00-0.00%
VSMDVasamed, Inc.
$0.00+0.00%
BIIOBionovate Technologies Corp
$0.00+0.00%
ATRXAdhera Therapeutics Inc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About PROT

What is the current price of Proteonomix?

Proteonomix is trading at $0.00 per share.

What is the 52-week range for Proteonomix?

Over the past 52 weeks, Proteonomix has traded between $0.00 and $0.00.

How much debt does Proteonomix have?

Proteonomix total debt is unavailable.

How much cash does Proteonomix have on hand?

Proteonomix does not have cash on hand data available.

What is Proteonomix’s dividend yield?

Proteonomix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.